Navigation Links
Landscape for Lung Cancer Therapies is Focus of New Post-ASCO MedPredict Report
Date:6/26/2008

SCOTTSDALE, Ariz., June 26 /PRNewswire/ -- MedPredict has published a new report in its oncology series entitled "Thought Leader Insight & Analysis: Lung Cancer," designed to provide critical strategic insight for pharma and biotech companies with a stake in the market for diagnostics and treatments in non-small cell and small cell lung cancer.

The big news at the recent American Society of Clinical Oncology (ASCO) meeting was the presentation of the Erbitux FLEX clinical trial data showing increased overall survival in EGFR-positive first-line non-small cell lung cancer. In light of these positive results, MedPredict's panel addresses the following questions: Is Erbitux useful in those 40% of patients who are Avastin-ineligible? Is Erbitux useful in the 24% patients who aren't getting Avastin but in theory could? Is Erbitux going to legitimately threaten Avastin in an Avastin-eligible patient?

MedPredict's panel also reviews recent advances in other mechanistic approaches to treatment, including angiogenesis/VEGF, vascular disrupting agents, anthracyclines, TRAIL / DR4 / DR5, Bcl-2/Bcl-xL, survivin, cyclin dependent kinase, cMET, EGFR (T790M), antifolate, HDAC / epigenetics, Hedgehog, HSP90, IGF-1, MAGE-A3, MEK, microtubule, apoptosis, kinesin/EG5, aurora kinase, Polo-like kinase 1, mTOR, PI3/AKT, KRAS, and topoisomerase.

"This report will provide essential strategic insight for those involved in development of lung cancer therapies," according to MedPredict President Dr. Jeffrey Berk. "Our panelists discuss ongoing clinical programs, and offer their opinions on which of the myriad new drugs in development are likely to be significant improvements over current options."

Some of the companies/partnerships discussed in this report include: Abbott, Abraxis, Amgen, Angiogene, Antisoma, Ardea, Array, Ascenta, AstraZeneca, Bayer-Schering, Bristol-Myers Squibb, Boehringer Ingelheim, Concordia, Critical Outcome Technologies, Cytokinetics, Daiichi Sankyo, Eisai, Epicept, Exelixis, Genentech, GlaxoSmithKline, Human Genome Sciences, ImClone, Infinity, Lilly, Medimmune, Merck, Merck Serono, Nerviano, Novartis, Oncothyreon, OSI Pharmaceuticals, Piramed, Pfizer, Prolexys, Regeneron, Roche, Sanofi-Aventis, Semafore, Vertex.

The full report can be purchased by contacting MedPredict.

About MedPredict

MedPredict (http://www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.


'/>"/>
SOURCE MedPredict
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Avastin(R) Shows Unprecedented Benefits in Colorectal Cancer Patients, Irrespective of K-Ras Gene Mutation
2. CuraGen Announces Initiation of Phase II Trial of CR011-vcMMAE in Patients with Advanced Breast Cancer
3. Genmab Initiates Study of Zalutumumab With Radiotherapy in Head and Neck Cancer
4. First Breast Cancer Patient Receives Treatment in National Electronic Brachytherapy Registry Launched by Three Physician Societies
5. CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
6. GlaxoSmithKline Collaborates with National Cancer Institute to Make Large Body of Cancer Cell Genomic Data Available to All Cancer Researchers
7. New Australian Technology: Detecting Breast Cancer With Hair
8. GeneGo is Awarded NCI Grant for Development of Systems Biology Platform for Integrative Data Analysis in Cancer
9. Fox Chase Cancer Center and VisEn Medical Announce Program to Advance First Clinical Trials of Novel Fluorescence Molecular Imaging Technologies
10. Bionovo Elucidates Mechanism of Breast Cancer Control by Estrogen Receptor Beta
11. Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... Calif. , June 23, 2016 ... CST on Thursday, July 7, 2016 , , , , ... ) , , , , EXPERT PANELISTS:  , , ... Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar ... The global pharmaceutical industry is witnessing an exceptional ...
(Date:6/23/2016)... -- Revolutionary technology includes multi-speaker listening to ... leaders in advanced audiology and hearing aid technology, has ... the world,s first internet connected hearing aid that opens ...      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ) , ... firsts,: , TwinLink™ - the first dual ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a ... fitness app plans to fix the two major problems leading the fitness industry today:, ... type program , They don’t eliminate all the reasons people quit their exercise ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
Breaking Medicine News(10 mins):